Abstract
Schools have been closed in the Philippines since March 2020 due to the COVID-19 pandemic. In 2022, the government already allowed a pilot run of limited in-person classes in low-risk areas. With such development, the present paper aims to explore the question “Is it safe to reopen schools with the current vaccination coverage?” We used an age-stratified COVID-19 agent-based model coupled with social contact probabilities to simulate school reopening and vaccination scenarios in the 17 regions of the country. Through these simulations, we found downtick points for infections and deaths—the vaccination coverage at which we do not expect increases in infections and deaths should schools reopen. We then calculated the School Reopening Viability (SRV) of the regions and visualized these scores with a stop-go map for school reopening. Simulation results suggest that all regions except Regions 7, 9, BARMM, and 13 can already reopen schools without the fear of upticks in infections nor deaths. These regions have lower vaccination coverages relative to the rest of the country, especially against the case of Luzon which has the highest vaccination coverage. We recommend that the areas of concern ramp up their vaccination efforts before reopening schools. At the same time, behavioral factors (mask-wearing, physical distancing, hand-washing) and disease resistance factors (healthy living habits) shall be enforced once schools reopen. Finally, school reopening shall be gradual to ensure the crafting of data-driven (hospital utilization, positivity rate) policies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding. Earlier studies (April-June, 2020) were funded by the UP Alumni Engineers.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
https://doh.gov.ph/covid-19/case-tracker. Accessed 30 March 2022. https://www.rappler.com/newsbreak/data-documents/tracker-covid-19-vaccines-distribution-philippines. Accessed 1 March 2022.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
We clarified that we did not distinguish the effects of each variant, and presented the cumulative effects of the variants that have been detected in the country at the time the simulations were run. We also clarified the captions on figures.
Data Availability
All data used in our simulations are available online. Our mathematical model has been well-described in previous publications. Our agent-based model is proprietary.
https://doh.gov.ph/covid-19/case-tracker
https://www.rappler.com/newsbreak/data-documents/tracker-covid-19-vaccines-distribution-philippines
Nomenclature
- COVID-19
- Coronavirus Disease of 2019
- DOH
- Department of Health Philippines
- PSA
- Philippine Statistics Authority
- SRV
- School Reopening Viability
- WHO
- World Health Organization